Electronic Monitoring in Medication Adherence Measurement

Poor adherence with prescribed therapy often results in decreased efficacy, annoying for patient both and physician. Negative health improvement adds extensive costs to the healthcare system. Thus, physicians need to carefully examine medication adherence before investigating possible pharmacologic reasons for drug failure or initiating alternative treatments and special diagnostic tests. Documenting medication adherence can also help with the development of new drugs and establishing optimized treatment regimens.Reliable distinction between non-adherence and nonresponse is a new issue for medicine, the pharmaceutical industry and its regulators. Investigation of adherence patterns has been established on evidence-based clinical and biostatistical research agendas.Originally, the term ‘compliance’ was used to describe how a patient adheres to a recommended therapy plan. Subsequently, ‘compliance’ has been changed to the more appropriate term ‘adherence’. Several approaches to studying the relationship between medication adherence and medical outcome exist. This article provides an overview on medical adherence and methods of measuring adherence, especially electronic monitoring.Traditional methods of adherence assessment (patient interview, diaries, questionnaires, pill counts, prescription refill surveys) often do not deliver reliable data. Thus, researchers have tried to approach adherence by measuring serum drug concentrations or other biologic or chemical markers to gain more objective data. However, the state of the art for analyzing adherence is the use of electronic monitoring devices, electronic event monitors. Such devices not only provide more reliable data but also more detailed data about actual patient adherence, such as dose frequency, dose time, dose interval and dose timing — details that traditional methods do not show. Electronic monitoring shows that poor adherence, especially dosage omission or changing intervals, is more prevalent than previously recognized. The detailed adherence patterns provided by electronic monitoring show the need for a new kind of drugs. These drugs should provide good therapeutic coverage despite dosage omission and are therefore called ‘forgiving pharmaceuticals’.Adherence and medical outcome have been extensively studied in patients with psychiatric disorders, hypertension and other cardiovascular disorders and most recently in patients receiving HIV/AIDS therapy. But non-adherence can be found in any medical field. Regarding the lack of equivalent studies on adherence and therapeutic efficacy in treating skin diseases, this topic should be looked at more closely in dermatology. Recalcitrant atopic dermatitis, psoriasis, tinea pedis and acne would be ideal study areas.

[1]  M. Kass,et al.  Compliance with topical pilocarpine treatment. , 1986, American journal of ophthalmology.

[2]  D. Hull,et al.  Noncompliance in Organ Transplant Recipients , 1989, Transplantation.

[3]  J Urquhart,et al.  The Electronic Medication Event Monitor , 1997, Clinical pharmacokinetics.

[4]  T F Blaschke,et al.  Medication compliance as a feature in drug development. , 1997, Annual review of pharmacology and toxicology.

[5]  W. P. Munroe,et al.  Impact of an Electronic Medication Compliance Aid on Long‐Term Blood Pressure Control , 1992, Journal of clinical pharmacology.

[6]  P. Meredith Therapeutic implications of drug "holidays'. , 1996, European heart journal.

[7]  J. Cramer,et al.  Relationship between medication compliance and medical outcomes. , 1995, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[8]  J. Cramer Compliance with contraceptives and other treatments. , 1996, Obstetrics and gynecology.

[9]  J. Cramer,et al.  How often is medication taken as prescribed? A novel assessment technique. , 1989, JAMA.

[10]  Joyce A. Cramer,et al.  Patient Compliance in Medical Practice and Clinical Trials , 1991 .

[11]  Désirée van der Heijde,et al.  Facilitated analysis of data on drug regimen compliance. , 1997 .

[12]  M. Kass,et al.  Compliance with topical timolol treatment. , 1987, American journal of ophthalmology.

[13]  P. Rudd,et al.  Antihypertensive medication-taking. Investigation of a simple regimen. , 1993, American journal of hypertension.

[14]  P. Rudd,et al.  Pharmacokinetics as an Aid to Optimising Compliance with Medications , 1995, Clinical pharmacokinetics.

[15]  H. Norton,et al.  Impact of Compliance and Side Effects on the Clinical Outcome of Patients Treated With Oral Erythromycin , 1994, Pharmacotherapy.

[16]  D. Piacquadio,et al.  The critical role of the vehicle to therapeutic efficacy and patient compliance. , 1998, Journal of the American Academy of Dermatology.

[17]  John Urquhart,et al.  Role of Patient Compliance in Clinical Pharmacokinetics , 1994 .

[18]  C. Rand,et al.  Noncompliance and treatment failure in children with asthma. , 1996, The Journal of allergy and clinical immunology.

[19]  J. Witkowski Compliance: The Dermatologic Patient , 1988, International journal of dermatology.

[20]  C Desforges,et al.  Dose Frequency and Dose Interval Compliance with Multiple Antiepileptic Medications During a Controlled Clinical Trial , 1995, Epilepsia.

[21]  J. Urquhart,et al.  Impact of Unrecognized Dosing Errors on the Cost and Effectiveness of Pharmaceuticals , 1988 .

[22]  J. Urquhart Can drug delivery systems deliver value in the new pharmaceutical marketplace? , 2003, British journal of clinical pharmacology.

[23]  C. Rand,et al.  Improving inhaler adherence in a clinical trial through the use of the nebulizer chronolog. , 1993, Chest.

[24]  S. Spector,et al.  Compliance in clinical trials of two nonbronchodilator, antiasthma medications. , 1991, Annals of allergy.

[25]  W. Bilker,et al.  Potential utility of electronic drug compliance monitoring in measures of adverse outcomes associated with immunosuppressive agents , 1999, Pharmacoepidemiology and drug safety.

[26]  Enhancing patients' compliance , 1998, BMJ.

[27]  S. Bartuś,et al.  Noncompliance in organ transplant recipients. , 1990, Transplantation.

[28]  M. Trimble,et al.  Epilepsy and Quality of Life , 1994 .

[29]  Susan Swindells,et al.  Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV Infection , 2000, Annals of Internal Medicine.

[30]  A. Wessling,et al.  Pharmaceutical care for patients with skin diseases: a campaign year at Swedish pharmacies , 1995, Journal of clinical pharmacy and therapeutics.

[31]  F. Tremel,et al.  Use of a microprocessor-equipped tablet box in monitoring compliance with antihypertensive treatment. , 1992, Journal of cardiovascular pharmacology.

[32]  I. Litt,et al.  Compliance with therapeutic regimens. , 1984, Journal of adolescent health care : official publication of the Society for Adolescent Medicine.

[33]  R. Didlake,et al.  Patient noncompliance: a major cause of late graft failure in cyclosporine-treated renal transplants. , 1988, Transplantation proceedings.

[34]  P. Rudd,et al.  Improved compliance measures: Applications in an ambulatory hypertensive drug trial , 1990, Clinical pharmacology and therapeutics.

[35]  Bernard,et al.  Advances in Drug Research , 1964 .

[36]  J Urquhart,et al.  Contending paradigms for the interpretation of data on patient compliance with therapeutic drug regimens. , 1998, Statistics in medicine.

[37]  J. Urquhart Correlates of variable patient compliance in drug trials: Relevance in the new health care environment , 1995 .